Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 338

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression

Open access
Aguilar, E.J., Ricciuti, B., Gainor, J.F., Kehl, K.L., Kravets, S., Dahlberg, S., Nishino, M., Sholl, L.M., Adeni, A., Subegdjo, S., Khosrowjerdi, S., Peterson, R.M., Digumarthy, S., Liu, C., Sauter, J., Rizvi, H., Arbour, K.C., Carter, B.W., Heymach, J.V., Altan, M., Hellmann, M.D., Awad, M.M. · 2019 · Annals of Oncology

Abstract

BACKGROUND: In non-small-cell lung cancers with programmed death-ligand 1 (PD-L1) expression on ≥50% of tumor cells, first-line treatment with the PD-1 inhibitor pembrolizumab improves survival compared with platinum-doublet chemotherapy. Whether higher PD-L1 levels within the expression range of 50%-100% predict for even greater benefit to pembrolizumab is currently unknown. PATIENTS AND METHODS: In this multicenter retrospective analysis, we analyzed the impact of PD-L1 expression levels on the overall response rate (ORR), median progression-free survival (mPFS), and median overall survival (mOS) in patients who received commercial pembrolizumab as first-line treatment of non-small-cell lung cancer (NSCLC) with a PD-L1 expression of ≥50% and negative for genomic alterations in the EGFR and ALK genes . RESULTS: Among 187 patients included in this analysis, the ORR was 44.4% [95% confidence interval (CI) 37.1% to 51.8%], the mPFS was 6.5 months (95% CI 4.5-8.5), and the mOS was not reached. The median PD-L1 expression level among patients who experienced a response to pembrolizumab was significantly higher than among patients with stable or progressive disease (90% versus 75%, P < 0.001). Compared with patients with PD-L1 expression of 50%-89% (N = 107), patients with an expression level of 90%-100% (N = 80) had a significantly higher ORR (60.0% versus 32.7%, P < 0.001), a significantly longer mPFS [14.5 versus 4.1 months, hazard ratio (HR) 0.50 (95% CI 0.33-0.74), P < 0.01], and a significantly longer mOS [not reached versus 15.9 months, HR 0.39 (95% CI 0.21-0.70), P = 0.002]. CONCLUSION: Among patients with NSCLC and PD-L1 expression of ≥50% treated with first-line pembrolizumab, clinical outcomes are significantly improved in NSCLCs with a PD-L1 expression of ≥90%. These findings have implications for treatment selection as well as for clinical trial interpretation and design.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/annonc/mdz288

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 23 references

Cited by

See all 338

Metadata

Authors
Aguilar, E. J., Ricciuti, B., Gainor, J. F., Kehl, K. L., Kravets, S., Dahlberg, S., Nishino, M., Sholl, L. M., Adeni, A., Subegdjo, S., Khosrowjerdi, S., Peterson, R. M., Digumarthy, S., Liu, C., Sauter, J., Rizvi, H., Arbour, K. C., Carter, B. W., Heymach, J. V., Altan, M., Hellmann, M. D., & Awad, M. M.
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2019-10
Volume
30
Issue
10
Pages
1653-1659
ISSN
0923-7534 (ISSN-L)
OpenAlex
W2969539132
Cited by
338
References
23
FWCI
15.24
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression. https://app.cochat.ai/papers/10.1093/annonc/mdz288
The paper
Aguilar, E. J., Ricciuti, B., Gainor, J. F., Kehl, K. L., Kravets, S., Dahlberg, S., Nishino, M., Sholl, L. M., Adeni, A., Subegdjo, S., Khosrowjerdi, S., Peterson, R. M., Digumarthy, S., Liu, C., Sauter, J., Rizvi, H., Arbour, K. C., Carter, B. W., Heymach, J. V., . . . Awad, M. M. (2019). Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression. Annals of Oncology. https://doi.org/10.1093/annonc/mdz288

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.